{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Los+Angeles&page=29&state=California",
    "query": {
      "state": "California",
      "city": "Los Angeles",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 4637,
    "total_pages": 464,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Los+Angeles&page=30&state=California&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Los+Angeles&page=28&state=California&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-08T00:59:57.956Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07299019",
      "title": "A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Secondary Progressive Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Orelabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zenas BioPharma (USA), LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 990,
      "start_date": "2026-03-23",
      "completion_date": "2030-07",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-08T00:59:57.956Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07299019"
    },
    {
      "nct_id": "NCT01186328",
      "title": "EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoblastic Leukemia, Acute",
        "Lymphoblastic Leukemia, Acute, Childhood",
        "Leukemia, Lymphoblastic, Acute, T Cell",
        "Leukemia, Lymphoblastic, Acute"
      ],
      "interventions": [
        {
          "name": "EZN-3042",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "PEG-asparaginase",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Hydrocortisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 6,
      "start_date": "2010-08-24",
      "completion_date": "2012-01-10",
      "has_results": true,
      "last_update_posted_date": "2024-02-01",
      "last_synced_at": "2026-11-08T00:59:57.956Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01186328"
    },
    {
      "nct_id": "NCT07287800",
      "title": "TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hypogonadism, Male",
        "End Stage Renal Disease (ESRD)",
        "Kidney Transplant"
      ],
      "interventions": [
        {
          "name": "Testosterone Replacement Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 50,
      "start_date": "2025-07-01",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-11-08T00:59:57.956Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07287800"
    },
    {
      "nct_id": "NCT00646230",
      "title": "N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "fenretinide",
          "type": "DRUG"
        },
        {
          "name": "high performance liquid chromatography",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "New Approaches to Neuroblastoma Therapy Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "0 Years to 30 Years"
      },
      "enrollment_count": 17,
      "start_date": "2006-12",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-11-08T00:59:57.956Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00646230"
    },
    {
      "nct_id": "NCT06991114",
      "title": "AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Refractory Rheumatoid Arthritis (RA)",
        "Idiopathic Inflammatory Myopathies (IIMs)",
        "Systemic Sclerosis (SSc)",
        "Rheumatoid Arthritis (RA",
        "IIM",
        "Myositis",
        "Scleroderma",
        "Sjogren Syndrome",
        "Sjogrens Disease"
      ],
      "interventions": [
        {
          "name": "Allogeneic NK Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Artiva Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2025-07-09",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-11-08T00:59:57.956Z",
      "location_count": 31,
      "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more",
      "locations": [
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06991114"
    },
    {
      "nct_id": "NCT06505811",
      "title": "Mixed Methods Evaluation of the Pomona Household Universal Grant (HUG) Program",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Early Child Well-being",
        "Parental Stress",
        "Family Economic Security",
        "Parental/Caregiver Health",
        "Mental Health"
      ],
      "interventions": [
        {
          "name": "Guaranteed Income ($500/monthly)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Active Comparison ($20/monthly)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 599,
      "start_date": "2024-06-17",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-08T00:59:57.956Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06505811"
    },
    {
      "nct_id": "NCT06278311",
      "title": "Correlation of Toxins With Gastrointestinal (GI) and Overall Health",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Gastrointestinal Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Vibrant America Clinical Lab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2025-02",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-11-08T00:59:57.956Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Santa Clara, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Clara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06278311"
    },
    {
      "nct_id": "NCT02867592",
      "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adrenal Cortical Carcinoma",
        "Alveolar Soft Part Sarcoma",
        "Central Nervous System Neoplasm",
        "Childhood Clear Cell Sarcoma of Soft Tissue",
        "Clear Cell Sarcoma of Soft Tissue",
        "Ewing Sarcoma",
        "Hepatoblastoma",
        "Hepatocellular Carcinoma",
        "Osteosarcoma",
        "Recurrent Adrenal Cortical Carcinoma",
        "Recurrent Alveolar Soft Part Sarcoma",
        "Recurrent Clear Cell Sarcoma of Soft Tissue",
        "Recurrent Ewing Sarcoma",
        "Recurrent Hepatoblastoma",
        "Recurrent Hepatocellular Carcinoma",
        "Recurrent Kidney Wilms Tumor",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Osteosarcoma",
        "Recurrent Primary Malignant Central Nervous System Neoplasm",
        "Recurrent Renal Cell Carcinoma",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Recurrent Thyroid Gland Medullary Carcinoma",
        "Refractory Adrenal Cortical Carcinoma",
        "Refractory Alveolar Soft Part Sarcoma",
        "Refractory Clear Cell Sarcoma of Soft Tissue",
        "Refractory Ewing Sarcoma",
        "Refractory Hepatoblastoma",
        "Refractory Hepatocellular Carcinoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Osteosarcoma",
        "Refractory Primary Central Nervous System Neoplasm",
        "Refractory Primary Malignant Central Nervous System Neoplasm",
        "Refractory Renal Cell Carcinoma",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma",
        "Refractory Thyroid Gland Medullary Carcinoma",
        "Refractory Wilms Tumor",
        "Renal Cell Carcinoma",
        "Rhabdomyosarcoma",
        "Soft Tissue Sarcoma",
        "Solid Neoplasm",
        "Thyroid Gland Medullary Carcinoma",
        "Wilms Tumor"
      ],
      "interventions": [
        {
          "name": "Cabozantinib",
          "type": "DRUG"
        },
        {
          "name": "Cabozantinib S-malate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "2 Years to 30 Years"
      },
      "enrollment_count": 109,
      "start_date": "2017-05-18",
      "completion_date": "2027-06-28",
      "has_results": true,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-11-08T00:59:57.956Z",
      "location_count": 142,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 104 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bellflower",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02867592"
    },
    {
      "nct_id": "NCT01158807",
      "title": "Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hereditary Hemorrhagic Telangiectasia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Unity Health Toronto",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 2272,
      "start_date": "2010-04-08",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-22",
      "last_synced_at": "2026-11-08T00:59:57.956Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01158807"
    },
    {
      "nct_id": "NCT00000893",
      "title": "Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Nelfinavir mesylate",
          "type": "DRUG"
        },
        {
          "name": "Efavirenz",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "3 Months to 16 Years"
      },
      "enrollment_count": 103,
      "start_date": "1997-10",
      "completion_date": "2002-12",
      "has_results": false,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-11-08T00:59:57.956Z",
      "location_count": 25,
      "location_summary": "Long Beach, California • Los Angeles, California • Oakland, California + 16 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000893"
    }
  ]
}